Publication date: 18/07/2018
Belgian based skin microbiome research pioneer S-Biomedic successfully closed the first round of its Series A financing. In addition to a significant investment from lead investor Beiersdorf, S-Biomedic also secured an investment from the Swiss digital VC investiere.ch, as well as previous contributions from Johnson & Johnson Innovation – JJDC, Inc.
What sets S-Biomedic’s patented technology apart from the numerous life science start-ups in this field is the combination of a unique pathogenicity biomarker with targeted modulation of bacterial compositions directly sourced from healthy human skin.
Based upon the positive results from its acne vulgaris microbiome research program, S-Biomedic recently established a collaboration with skin care global leader Beiersdorf which leverages S-Biomedic’s unique proprietary technology in the skin microbiome field. “Skin Care is on the verge of disruption and will hugely benefit from the dramatic progress in life science research. Microbiome research is one of the most dynamic fields, and we need to deeply look at it for innovative offers for our consumers.” said Dr. May Shana’a, Senior Corporate Vice President of R&D for Beiersdorf. “We are delighted to tap into Beiersdorf’s vast experience in skin care to take our research to the next stage of commercialization with maximum speed and efficiency,” said Veronika Oudova, CEO of S-Biomedic.
S-Biomedic was founded by three pioneers in the microbiome research field: Veronika Oudova, Bernard Paetzold and Marc Guell who managed to file a 1st patent for a targeted microbiome modulation technology enabling to transplant beneficial bacteria on the skin back in 2015.
”We were excited by the rare combination of a formidable team, a compelling technology and strategic collaboration with industry giants”, says Investment Manager Michael Blank, explaining investiere.ch’s motivation to join this Series A. “In our opinion, S-Biomedic has all the ingredients to blaze a new trail in the skin microbiome field.”
“The collaboration with Beiersdorf will enable us to tap into their vast experience in skin care, accelerating our research into the next stage of commercialization with maximum speed and efficiency”, comments Veronika Oudova, CEO of S-Biomedic.
Motivated by acclaimed studies showing the unmet needs in treatment of dandruff and ageing related skin diseases, S-Biomedic initiated the early stage concept development of two more skin care programs in these domains.
To extend the pipeline with these research programs, S-Biomedic is looking forward to the 2nd closing of Series A round in September 2018.
S-Biomedic is a Belgium based life science company exploring the unexploited cosmetic and therapeutic potential of the skin microbiome. The skin microbiome – a habitat of billions of beneficial and harmful bacteria-contributes to a healthy skin. An imbalance of these bacteria can lead to a variety of skin problems. The skin microbiome offers unparalleled skincare and clinical opportunities for a wide range of unmet medical conditions. This represents a unique opportunity for the commercial development of break-through cosmetic and dermatological products. In this field, S-Biomedics has developed a lead program focusing on acne. Simultaneously, two early stage concept development programs have been initiated focusing on ageing and dandruff. S-Biomedics is a resident company of Johnson & Johnson Innovation, JLABS, (JLABS @ BE) in Beerse Belgium.